Gastric acid suppression is associated with decreased erlotinib efficacy in non–small-cell lung cancer
MP Chu, S Ghosh, CR Chambers, N Basappa… - Clinical lung cancer, 2015 - Elsevier
… This large population-based study suggests erlotinib efficacy might be linked with gastric pH
… coadministration of erlotinib with AS therapy. Further prospective investigation is warranted. …
… coadministration of erlotinib with AS therapy. Further prospective investigation is warranted. …
Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib
LH Lam, EV Capparelli, R Kurzrock - Cancer chemotherapy and …, 2016 - Springer
… interactions that may alter the safety or efficacy of therapy. … the frequency of acid-suppression
therapy use with erlotinib and … events in patients receiving erlotinib as standard of care. …
therapy use with erlotinib and … events in patients receiving erlotinib as standard of care. …
An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib
… Our study raises the possibility that AS use may have less effect erlotinib concentrations
and efficacy in the general population then may have been predicted by the single-dose PK …
and efficacy in the general population then may have been predicted by the single-dose PK …
[HTML][HTML] Effect of acid suppressants on the efficacy of tyrosine kinase inhibitors in patients with epidermal growth factor receptor‑mutated non‑small‑cell lung cancer
K Miyazaki, S Sato, T Kodama… - Molecular and …, 2016 - spandidos-publications.com
… is not associated with decreased efficacy of gefitinib and erlotinib in patients with mutated …
that gastric acid suppression was associated with decreased erlotinib efficacy in NSCLC …
that gastric acid suppression was associated with decreased erlotinib efficacy in NSCLC …
Administration of erlotinib in apple juice overcomes decreased absorption in a rat model of gastric acid suppression
T Shimada, M Okano, M Yamada, Y Ogawa… - Drug Metabolism and …, 2020 - Elsevier
… Erlotinib shows pH-dependent solubility and its absorption is decreased in patients receiving
gastric acid suppression therapy. Here, we examined whether administration of erlotinib in …
gastric acid suppression therapy. Here, we examined whether administration of erlotinib in …
[PDF][PDF] Clinical impact of gastric acid suppressing medication on the effectiveness of tyrosine kinase inhibitors in lung cancer patients.
MN Sedano, JMC Teller, CG Muñoz, DF Redondo… - chemotherapy, 2018 - jbuon.com
… This study showed that antacids negatively affected the efficacy of erlotinib in both PFS (HR:1.83,
1.4 vs 2.3 months, p<0.001) and OS (HR:1.37, 12.9 vs 16.8 months, p=0.003) [21]. …
1.4 vs 2.3 months, p<0.001) and OS (HR:1.37, 12.9 vs 16.8 months, p=0.003) [21]. …
Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non–Small Cell Lung Cancer
M Ohgami, T Kaburagi, A Kurosawa… - Therapeutic drug …, 2018 - journals.lww.com
… acid suppressants reduced did 7,8 or did not affect efficacy. To … acid suppression resulted
in reduced intestinal absorption of erlotinib, obviously overriding a potential effect on erlotinib …
in reduced intestinal absorption of erlotinib, obviously overriding a potential effect on erlotinib …
[HTML][HTML] Impact of the gastric acid suppressant use on the safety and effectiveness of EGFR-TKIs: a systematic review and meta-analysis
X Du, W Liu, K Chen, Z Wang, X Li, L Yang… - Frontiers in …, 2022 - frontiersin.org
… acid suppressants (GASs) that are widely used for many indications requiring acid suppression…
H 2 RAs) or “gastric acid suppressant”) and (gefitinib or erlotinib or afatinib or icotinib or …
H 2 RAs) or “gastric acid suppressant”) and (gefitinib or erlotinib or afatinib or icotinib or …
Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers
J Ling, KA Johnson, Z Miao, A Rakhit, MP Pantze… - Drug metabolism and …, 2006 - ASPET
… , erlotinib avoids the normal tissue toxicity inherent to cytotoxic agents, eg, hematologic
suppression, … Preliminary efficacy of erlotinib has also been demonstrated in phase II trials in …
suppression, … Preliminary efficacy of erlotinib has also been demonstrated in phase II trials in …
Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye
… Erlotinib exposure was reduced by ∼15% Erlotinib should be taken 10 h after H2-… compromise
therapeutic efficacy in some individuals. Due to the persistent acid suppression of proton-…
therapeutic efficacy in some individuals. Due to the persistent acid suppression of proton-…
相关搜索
- gastric acid suppression
- acid suppressive agents
- adverse event incidence acid suppression
- efficacy of erlotinib gefitinib in patients
- efficacy of gefitinib gastric acid suppressants
- erlotinib efficacy small cell lung cancer
- oncology patients acid suppression
- survival outcomes acid suppression
- efficacy of erlotinib egfr mutations
- efficacy of erlotinib medication use
- efficacy of erlotinib clinical impact
- efficacy of erlotinib lung cancer